Stifel Starts Neumora Therapeutics (NMRA) at Buy, 'Bullish on Navacaprant, Pipeline Optionality'
Tweet Send to a Friend
(Updated - October 10, 2023 4:47 AM EDT)
Stifel analyst Paul Matteis initiates coverage on Neumora Therapeutics (NASDAQ: NMRA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Paul Matteis initiates coverage on Neumora Therapeutics (NASDAQ: NMRA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
